Hsbc Holdings PLC Has $668,000 Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI)

Hsbc Holdings PLC raised its holdings in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 83.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,642 shares of the company’s stock after acquiring an additional 13,454 shares during the quarter. Hsbc Holdings PLC’s holdings in Denali Therapeutics were worth $668,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. GAMMA Investing LLC grew its position in Denali Therapeutics by 879.5% during the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock valued at $48,000 after purchasing an additional 1,847 shares in the last quarter. PNC Financial Services Group Inc. increased its stake in shares of Denali Therapeutics by 48.1% in the fourth quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after acquiring an additional 807 shares during the last quarter. Fisher Asset Management LLC purchased a new stake in shares of Denali Therapeutics during the fourth quarter worth $59,000. Headlands Technologies LLC acquired a new stake in Denali Therapeutics during the first quarter valued at $88,000. Finally, SG Americas Securities LLC purchased a new position in Denali Therapeutics in the first quarter valued at about $147,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on DNLI shares. HC Wainwright reaffirmed a “buy” rating and set a $90.00 price target on shares of Denali Therapeutics in a research note on Wednesday, September 4th. Citigroup boosted their target price on shares of Denali Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Wedbush cut their price target on shares of Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. JPMorgan Chase & Co. lifted their price objective on shares of Denali Therapeutics from $28.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, Bank of America increased their target price on shares of Denali Therapeutics from $25.00 to $29.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $38.33.

Denali Therapeutics Price Performance

Denali Therapeutics stock opened at $29.43 on Monday. The firm has a market cap of $4.20 billion, a price-to-earnings ratio of -30.66 and a beta of 1.37. The firm has a fifty day moving average price of $25.44 and a two-hundred day moving average price of $21.81. Denali Therapeutics Inc. has a fifty-two week low of $14.56 and a fifty-two week high of $32.13.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, August 1st. The company reported ($0.59) earnings per share for the quarter, beating the consensus estimate of ($0.68) by $0.09. The business had revenue of $1.00 million for the quarter, compared to the consensus estimate of $10.00 million. During the same quarter in the previous year, the company earned $1.30 EPS. Denali Therapeutics’s revenue for the quarter was down 99.7% compared to the same quarter last year. As a group, sell-side analysts expect that Denali Therapeutics Inc. will post -2.54 earnings per share for the current year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.